3 completed, 1 active not recruiting. 3 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Active not recruiting 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 2 | Active not recruiting 1, Completed 1 |
Follow Abcuro, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis Ulviprubart (ABC008) - Inclusion Body Myositis (IBM) | Phase 2 / Phase 3 | Active not recruiting | Abcuro, Inc. | 270 | 2024-10-21 | 2025-07-28 |
| A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis ABC008 - Inclusion Body Myositis | Phase 2 / Phase 3 | Completed | Abcuro, Inc. | 272 | 2023-02-28 | 2026-10-01 |
| ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL) ABC008 - T-cell Large Granular Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Abcuro, Inc. | 21 | 2022-09-28 | 2026-05-06 |
| A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM) ABC008 - Inclusion Body Myositis | Phase 1 | Completed | Abcuro, Inc. | 19 | 2021-05-25 | 2025-02-20 |
Myositis, Inclusion Body (3) · Leukemia, Large Granular Lymphocytic (1) · Muscular Diseases (1) · Myositis (1) · Nervous System Diseases (1) · Neuromuscular Diseases (1)
Australia (3) · United States (3) · Belgium (1) · Canada (1) · France (1) · Germany (1) · United Kingdom (1)